UPDATES ON CLINICAL EVIDENCE AND INTERNATIONAL GUIDELINE FOR TROP2-TARGETING ADC IN THE TREATMENT OF ADVANCED/METASTATIC TRIPLE-NEGATIVE BREAST CANCER

Giới thiệu

The treatment of advanced/metastatic triple-negative breast cancer (mTNBC) continues to evolve, with new clinical data emerging alongside advances in TROP2-targeting antibody-drug conjugates (ADCs).